Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SMRP



This biomarker is also known as:
  • MSLN,
  • Soluble Mesothelin Related Peptide,

View in BioMuta


Soluble mesothelin-related protein (SMRP) is related to the mesothelin family of molecules. It is overexpressed in ovarian cancer, malignant pleural mesothelioma (MPM), and certain other cancers. One hypothesis for the origin of SMRP is that this mesothelin-like molecule was released from tumor cells into culture supernatants, sera, and malignant effusions from certain tumors. Another hypothesis is that SMRP is actually a proteolytically cleaved fragment of membrane-bound mesothelin. Currently SMRP is considered to be an isoform of mesothelin (MSLN). UniprotKB/SwissProt lists isoform 3 of human mesothelin (identifier Q13421-2) as SMRP.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Under Review


Differentially expressed mesothelial protein. May comprise a biomarker panel with SPP1 (osteopontin). SMRP can be assayed using MESOMARK, a 2-step immunoenzymatic assay in an ELISA format with a 6-point calibration curve. The MESOMARK assay may be useful for the detection and management of mesothelioma.

Performance Comment

SMRP is a promising biomarker for malignant pleural mesothelioma (MPM) in both serum and pleural effusion fluid.



Phase: Two
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.